Summary
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally
administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous
Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS).
Patients enrolling in the Phase 1 portion of the study must meet one of the following
criteria prior to consenting to the study:
- R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor
- R/R AML with spliceosome mutations of SF3B1 or U2AF1
- R/R hrMDS with spliceosome mutations of SF3B1 or U2AF1
- Number of pretreatments: 1 or 2
The Phase 2a Dose Expansion will be in 3 Cohorts of patients:
1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor;
2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and
3. R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1.
All patients above have had = 2 lines of prior systemic anticancer treatment. In previous
versions of this protocol there was a Phase 1b portion of the study, in which patients with
AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no
longer open for enrollment.